Menu
Menu
MIGS Reinvented: eyeFlow featured in Glaucoma Today
eyeFlow, Inc. is developing a highly effective micro-invasive device for the treatment of the world’s largest cause of irreversible blindness that is:
Dual-Action Innovation
eyeFlow replaces Glaucoma drop medication therapy through mechanical stenting paired with sustained, localized drug delivery.
Straightforward
eyeFlow takes Micro Invasive Glaucoma Surgery to the next level with the most accessible, intuitive procedure to date
High Growth Market
eyeFlow is the “Best In Class” of Micro Invasive Glaucoma Surgery which dominates the $5.7 billion Glaucoma treatment market
High Growth Market
eyeFlow is the “Best In Class” of Micro Invasive Glaucoma Surgery which dominates the $5.7 billion Glaucoma treatment market
In early pre-clinical trials, eyeFlow’s Micro Invasive Glaucoma Surgery (MIGS) device has produced very promising results and astonished a World-Renowned Ophthalmologist:
“My early implant experience with eyeflow has been outstanding. I believe its unique design and delivery system is going to appeal to a wide range of physicians and patients as it offers the most consistent mode of implantation.”
Arsham Sheybani, MD
Key Opinion Leader – Micro Invasive Glaucoma Surgery
The eyeFlow microstent is an investigational device and is not yet approved by the FDA. Its safety and effectiveness have not been established in the United States.